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Abstract
Risk factors for breast cancer are related to endogenous hormones and reproductive events.
As such, traditional cancer prevention strategies are not easily applicable. Tamoxifen and
other selective estrogen receptor modulators (SERMs) offer a new preventive strategy for
some high-risk women, but have not yet been shown to be efficacious for all women. New
tools to identify high-risk women are needed. One such tool is the development of a
multigenic model of breast cancer susceptibility that can be used to screen women in order
to identify those who carry a combination of alleles that puts them at significantly increased
risk.
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Introduction
The traditional view of public health prevention strategies
considers three broad categories. Primary prevention
involves activities that are aimed at reducing and removing
agents that increase risk. Secondary prevention includes
early detection activities that are designed to reduce mor-
tality. Finally, tertiary prevention aims to minimize or reduce
long-term disability and suffering. Cancer prevention
usually implies activities involved in primary or secondary
prevention. For many cancer sites, we have made signifi-
cant contributions in prevention. For example, the Pap
smear has had a great impact on cervical cancer, and
refrigeration and other safe food preservation practices
have markedly reduced the incidence of stomach cancer.
Largely because of the underlying hormonal etiology,
however, primary prevention strategies for breast cancer
have been limited.
Breast cancer risk factors
The biggest determinants of breast cancer risk are related to
endogenous hormone levels and major reproductive events,
and thus do not lend themselves to traditional prevention
strategies. Table 1 lists the established breast cancer risk
factors. Those with the greatest impact on risk are listed first,
and unfortunately are the most difficult to modify by tradi-
tional public health measures. For example, surgical removal
of the ovaries can hasten the onset of menopause, but is not
considered a reasonable approach to reduce the risk of
breast cancer. Age at menarche and the establishment of
regular menstrual cycles may be delayed by vigorous physi-
cal activity and possibly diet, but rarely is breast cancer pre-
vention a concern before menarche occurs.
Limiting the use of alcohol, hormone replacement therapy
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breast cancer, but the impact of these factors on breast
cancer risk are modest. Furthermore, these agents have
significant beneficial effects on the risks of other chronic
diseases, and these risk–benefit ratios must be carefully
weighed. Prolonged lactation may offer a small reduction
in breast cancer risk, but is not likely to be readily
accepted as a risk reduction strategy. The benefit of physi-
cal activity after menarche for the purpose of reducing
breast cancer risk is unclear. Because physical activity
can curb weight gain, it can be seen as an important pre-
ventive measure because postmenopausal obesity
increases breast cancer risk. Although the literature is
mixed on whether dietary fat and fiber are important in
breast cancer etiology, these factors are readily modifi-
able. However, the effect of moderate dietary changes on
breast cancer risk are likely to be small, at best.
Selective estrogen receptor modulators for
breast cancer prevention
The newest hope in the area of breast cancer prevention
came from the findings of a highly publicized tamoxifen
trial reported in 1998 [1]. These data provided the first
information from a randomized clinical trial to support the
hypothesis that breast cancer can be prevented among
high-risk women. Tamoxifen reduced the risk of invasive
breast cancer by 49% (P<0.00001) and noninvasive
breast cancer by 50% (P<0.002). The effect was limited
to estrogen receptor-positive tumors. Two smaller trials
[2,3] failed to find a benefit with tamoxifen; however, these
seemingly different results may be due largely to differ-
ences in the age and family history of the populations
studied, and (at least in one study) poor compliance with
the treatment regimen [4].
At present, we do not know whether the Breast Cancer
Prevention Trial (BCPT, NSABP-P1) [1] tamoxifen findings
are generalizable to all groups of women, such as those
with  BRCA mutations or women from ethnic minority
groups. We do not know whether the decreased inci-
dence observed among tamoxifen users was due to a
delay in the development of occult tumors that would ulti-
mately be diagnosed after cessation of tamoxifen use. If
so, how long can tamoxifen be safely administered. Finally,
none of the studies to date have provided reliable data on
mortality. The risks of tamoxifen chemoprevention must be
weighed carefully against its benefits. Although tamoxifen
reduces the risk of certain breast cancers and bone frac-
tures, it increases the risk of endometrial cancer. Whether
tamoxifen can reduce the incidence of heart disease is
unknown, and data from the BCPT [1] suggest that the
drug may increase the risk of stroke and cataracts. (See
Gail et al [5] for a complete discussion of the risks and
benefits of tamoxifen chemoprevention.)
Raloxifene is another SERM that has recently been sug-
gested to reduce the risk of estrogen receptor-positive
breast cancer, but without the subsequent increased risk
of endometrial cancer [6]. However, that study also needs
further confirmation and careful follow up.
Multigenic model of breast cancer
susceptibility
What more can be done to reduce the risk of breast
cancer? A long-standing strategy of risk reduction involves
targeting intervention efforts toward high-risk groups, but
who is at high risk for breast cancer? One in eight women
in the USA will develop breast cancer, and we must find
more effective ways to identify these women early. One
possibility is to develop a multigenic model of breast
cancer susceptibility, and then screen women to determine
who carries a combination of alleles that puts them at sig-
nificantly increased risk. Given the large and compelling
body of epidemiologic and experimental evidence that
implicates estrogens in the etiology of human breast
cancer, we proposed a multigenic model of breast cancer
predisposition that includes genes that are involved in
estrogen biosynthesis and intracellular binding [7•]. We
hypothesized that functionally relevant sequence variants in
such genes would act together, and also interact with well-
known hormonally related risk factors, to define a high-risk
profile for breast cancer. The term ‘functionally relevant
sequence variants’ refers to those mutations or polymor-
phisms that can be shown through laboratory experiments
to alter encoded protein structure or function, interaction
with other proteins, or half-life and stability within the cell.
Table 1
Breast cancer risk factors
Modifiable using
traditional intervention
strategies
Yes No
Factors that confer highest risk
Age ü
Inherited susceptibility ü
Atypical hyperplasia ü
Endogenous hormone levels ü
Early age at menarche ü
Late age at menopause ü
Late age at first pregnancy ü
Factors with small effects on risk
Physical activity ü
Lactation ü
Weight/body mass ü
HRT ü
Alcohol consumption ü
Possible risk factors that confer small risk
Oral contraceptive use ü
High dietary fat ü
Low dietary fiber ühttp://breast-cancer-research.com/content/2/4/277
We assumed that variation in genes that encode critically
important enzymes in estradiol biosynthesis would, individ-
ually, result in only modest differences in the rate of
biosynthesis. Presumably, there would be limited evolu-
tionary tolerance for major variation in hormone synthesis,
which could disrupt reproductive ability. However, a com-
bination of genes, each with minor variation in expressed
activity, could provide a degree of separation of risk that
would be clinically useful. These small variations could
result in a large cumulative effect after several decades.
For example, the model of breast tissue age by Pike et al
[8••] demonstrates that a 20% difference in levels of circu-
lating estrogen can result in a more than twofold increase
in lifetime breast cancer risk.
As shown in Figure 1, our original presentation of this
model included three genes of interest: the 17b-hydroxys-
teroid dehydrogenase 1 gene (HSD17B1), the
cytochrome p459c17a gene (CYP17), and the estrogen
receptor alpha gene (ESR1). We later added the aro-
matase gene (CYP19) to the model, although a functional
polymorphism was not known. Huang et al [9•] recently
reported their findings of a similar model with the estrogen
metabolizing genes CYP17; CYP1A1, which participates
in estrogen hydroxylation; and the catechol-O-methyltrans-
ferase gene (COMT), which encodes the enzyme that is
responsible for O-methylation leading to inactivation of
catechol estrogen. The numerous studies of other poly-
morphisms are reviewed elsewhere [10].
At present, data to support a role for CYP17 are most
compelling. As summarized below, this gene has been
shown to be associated with the risk of breast cancer,
serum hormone levels, age at menarche, and use of HRT.
CYP17 encodes the cytochrome p450c17a enzyme,
which functions at key branch points in human steroidoge-
nesis [11]. The 5¢-untranslated region of CYP17 contains
a single base-pair polymorphism that is 34 bp upstream
from the initiation of translation, and 27 bp downstream
from the transcription start site [12]. This base-pair
change creates a recognition site for the MspAI restriction
enzyme, and has been used to designate two alleles: A1
(the published sequence) and A2.
An association between risk for breast cancer and this
CYP17 polymorphism was first shown in 1997 [13]. In a
case–control study of incident breast cancer among
Asian, African-American and Latina women [13], we found
a 2.5-fold increased risk of advanced breast cancer asso-
ciated with the CYP17 A2 allele. That study also pre-
sented preliminary evidence suggesting that the CYP17
gene may be associated with age at menarche. The
reduced risk of breast cancer associated with a later age
at menarche was largely limited to A1/A1 women (odds
ratio 0.47, 95% confidence 0.22–0.98 for breast cancer
and later age at menarche) compared with women who
carried the A2 allele (odds ratio 0.80, 95% confidence
interval 0.51–1.27).
These results suggested that serum hormone levels may
differ by CYP17 genotype. We pursued this finding in a
separate study and found that the CYP17 genotype was
associated with serum estradiol and progesterone levels
among young nulliparous women [14]. As shown in
Figure 2, serum estradiol measured around day 11 of the
menstrual cycle was 11 and 57% higher (P=0.04),
respectively, among women heterozygous and homo-
Figure 1
Estrogen metabolism in the ovaries and breast epithelium and four
candidate genes that may play a role in breast cancer etiology. The
genes of interest are the cytochrome P450c17a gene (CYP17), the
aromatase cytochrome P450 gene (CYP19), the 17b-hydroxysteroid
dehydrogenase 1 gene (HSD17B1), and the estrogen receptor alpha
gene (ESR1).
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Figure 2
Geometric mean serum estradiol (E2) concentrations among young
nulliparous women on days 11 and 22 of the menstrual cycle by CYP17
genotype. Day 11 E2, P for trend 0.04; day 22 E2, P for trend 0.06.
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Day 22zygous for the CYP17 A2 allele compared with A1/A1
women. Similarly, around cycle day 22, serum estradiol
was 7 and 28% higher (P = 0.06) and progesterone
(Fig. 3) was 24 and 30% higher (P=0.04). These data
provide direct evidence of genetic control of serum
hormone levels, but the sample size was small and the
results need confirmation.
Finally, we recently reported that CYP17 is associated with
use of HRT [15•]. Among 749 postmenopausal women
aged 44–75 years at baseline randomly selected from a
larger multiethnic cohort, women who carry the CYP17
A2/A2 genotype were about half as likely as women with
the A1/A1 genotype to be current HRT users (odds ratio
0.52, 95% confidence interval 0.31–0.86). This associa-
tion was present in all four of the racial/ethnic groups that
were included in the study (white, African-American, Latino,
and Japanese), and for women above and below the
median weight of 150 pounds. Presumably, women with
the A2/A2 genotype have fewer indications for HRT use
due to their higher level of endogenous hormones.
Since this original study of CYP17 was published [13], at
least six other studies have reported on CYP17 and
breast cancer (Table 2) [9•,16–18,19•,20]. The results of
these subsequent studies were largely negative and
suggest heterogeneity by ethnicity. However, there may
be several reasons for the discrepant results.
The study by Dunning et al [16] is the largest to date but
had few advanced cases, and it did not examine the possi-
ble confounding effects of HRT. Four other smaller studies
[9•,17,18,20] found a modest elevation in breast cancer
risk with the CYP17 A2 allele in some subgroups, but
those findings did not reach statistical significance. Kris-
tensen et al [20] suggested that the effect of CYP17
might be limited to older patients (ie those aged over 55
years at diagnosis), which also may explain some of the
inconsistent results.
Breast Cancer Research    Vol 2 No 4 Feigelson and Henderson
Figure 3
Geometric mean serum progesterone concentrations among young
nulliparous women on day 22 of the menstrual cycle by CYP17
genotype (P for trend 0.04).
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Table 2
Summary of published studies of CYP17 and breast cancer
CYP17 (A2/A2 versus A1/A1) and breast cancer
Age of  Age of control All cases Advanced cases
Race/ patients individuals Advanced HRT use
Ref Study design ethnicity (years) (years) Cases (n) cases (n) OR 95% CI OR 95% CI considered?
[7•] Nested Afro-American, 63.0 ± 8.4 61.4 ± 8.3 174* 40 1.32† 0.87–2.0 2.5† 1.07–5.94 No
case–control Asian, Latina
[16] Case–control White <55 45–74 835 24 1.17 0.92–1.49 0.88† 0.38–2.01 No
[17] Nested White 60.4 ± 11.7 60.2 ± 11.5 115 30 0.89  0.41–1.95 1.39 0.26–7.28 Yes
case–control
[18] Case–control Afro-American Not given Not given 76 21 1.40† 0.44–4.38 0.6† 0.1–4.0 No
Latina 20 7 1.93† 0.75–5.01 0.2† 0.0–1.3
White 27 10 0.80† 0.45–1.43 1.7† 0.6–5.1
[19•] Nested White 58.3 ± 7.1‡ 464 107 0.91 0.61–1.34 0.84† 0.54–1.32 Yes
case–control
[9•] Case–control Taiwanese Not given Not given 150 Not given 1.28 0.73–2.27 Yes
[20] Case–control White 59 (27–91) 20–44 510 93§ 0.94 0.54–1.65 1.38§ 0.62–3.06 No
Ages are expressed as mean ± standard error, mean (range), or range. *Total cases, not specified by ethnicity; †odds ratio (OR) reflects A1/A2 +
A2/A2 combined; ‡age not specified by case–control status; §advanced cases over age 55 years.Only one study, that by Haiman et al [19•], was both sig-
nificantly larger than our original study and gave adequate
consideration to potential confounding. Those investiga-
tors did not find an association between CYP17 and
breast cancer. However, their results are compatible with
the potential modification of breast cancer risk due to late
age of menarche. As in our study (and one other [18]) the
protective effect of later onset of menarche was limited to
women with the A1/A1 genotype (odds ratio 0.57, 95%
confidence interval 0.36–0.90 for breast cancer and later
age at menarche). Furthermore, among 297 post-
menopausal women, those with the A2/A2 genotype had
statistically significantly elevated levels of estrone
(+14.2%,  P=0.01) and dehydroepiandrosterone
(+14.4%,  P=0.02), and modest nonsignificant elevations
in estradiol (+18.8%, P = 0.08), testosterone (+8.6%,
P=0.34), androstenedione (+17.1%, P=0.06), and dehy-
droepiandrosterone sulfate (+7.2%, P=0.26) compared
with women with the A1/A1 genotype. That study did not
show evidence of an association between CYP17 and
HRT use. However, the patterns of HRT use among a
cohort of predominately white nurses may be substantially
different from patterns of use among women in our multi-
ethnic cohort [15]. Additional studies are needed, but they
must be of sufficient size and quality to evaluate ade-
quately the role of CYP17 in advanced breast cancer
while examining the influence of HRT use and other poten-
tially important confounders and effect modifiers.
An important piece of information about CYP17 is still
missing. What is the functional relevance of this polymor-
phism, or what is it marking? It was recently shown [20]
that this T27C polymorphism in CYP17 converting the
sequence CACT into CACC does not influence Sp-1
binding, as had been suggested based on its similarity to
other known Sp-1 binding sequences. Gene function
studies are needed to determine whether the A2 allele
confers specifically a higher expression level of CYP17
[20]. Such studies will need to be carefully designed and
evaluated because we would not expect these polymor-
phisms to result in a large difference in circulating
hormone levels. Standard assays may not detect the rela-
tively small differences in activity we would predict from
the epidemiologic data.
Conclusion
The primary risk factors for breast cancer are not easily
modifiable because they stem from prolonged endoge-
nous hormonal exposures. The genetic basis of hormone
levels as an important risk factor for breast cancer has
only recently been recognized. It is now increasingly
obvious that genetic susceptibility, acting through
germline polymorphisms in metabolic genes, plays a criti-
cal role. Certainly the ‘complete’ multigenic model of
breast cancer susceptibility would include several impor-
tant genes. Further study is necessary to determine which
genes consistently predict known breast cancer risk
factors, serum hormone levels, and breast cancer.
The prevention and control of breast cancer is multidimen-
sional. First, we must identify the key genetic components
and use our knowledge of underlying genetic susceptibil-
ity to identify those women who are at highest risk.
Second, we must identify effective lifestyle modifications,
if any, that demonstrate a measurable and sustainable
reduction in risk. Third, we must develop earlier screening
tools using genetic markers of risk. Finally, we must
develop suitable chemopreventive agents, such as tamox-
ifen, that can prevent tumor development or progression.
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